Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 The reported safety ...
BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for ...
BELLEVUE, Wash. - OSR Holdings (NASDAQ:OSRH) received a notification from Nasdaq on September 5 that the company is not in compliance with the minimum bid price requirement of $1.00 per share, ...
The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study. VXM01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback